Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2025-07-24 DOI:10.1200/JCO-25-01680

Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castañón Álvarez, Caroline Robert, Juan F Rodríguez-Moreno, Ana Arance, Pablo Cerezuela-Fuentes, Henri Montaudié, Miguel F Sanmamed, María González-Cao, Julie Charles, María Pilar López Criado, Alfonso Berrocal, Enrique de Miguel, Elisa Funck-Brentano, Sorilla Prey, Mᵃ Carmen Álamo de la Gala, Ignacio Melero, Jose Antonio Avilés-Izquierdo, Ruth Roman, Beatriz Garcia-Pelaez, Sonia Rodriguez, Zuzana Jirakova Trnkova, Marisol Quintero, Sonia Maciá, Marya F Chaney, Stephane Dalle

引用次数: 0

查看原文本刊更多论文

bo112 + Pembrolizumab用于抗pd -1耐药晚期黑色素瘤患者：II期临床试验SPOTLIGHT-203。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.